logo

Minerva Neurosciences Inc (NERV)



Trade NERV now with
  Date
  Headline
6/24/2019 7:38:13 AM Minerva Reports Achievement Of Primary, Key Secondary Objectives In Phase 2b Trial Of Seltorexant In Insomnia
11/19/2018 8:15:06 AM Minerva Neurosciences Reports Results Of Dose Escalation Study Evaluating Roluperidone
11/5/2018 7:39:21 AM Minerva Neurosciences Q3 Loss Per Share $0.31 Vs Loss $0.28 Last Year
7/25/2018 8:05:00 AM Minerva Neurosciences Appoints Devin Smith As SVP And General Counsel
7/17/2018 4:06:48 PM Minerva Neurosciences Elects Jeryl Hilleman To Board Of Directors
5/3/2018 7:35:53 AM Minerva Neurosciences Posts Q1 Net Loss Of $12.4 Mln Or $0.32/share
4/9/2018 8:32:37 AM Minerva Neurosciences Screens First Patient In Phase 2b Trial Of MIN-117 To Treat Major Depressive Disorder
3/12/2018 7:36:35 AM Minerva Neurosciences Q4 Net Income $0.2 Mln Or Breakeven Per Share Vs Loss Of $9.4 Mln Or $0.27/Shr Last Year
2/5/2018 8:36:10 AM Minerva Neurosciences Names Rémy Luthringer Executive Chairman And William Doyle As Lead Independent Director